TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17604751

Group type: EXPERIMENTAL
Intervention: Super Size Me (experimental group, n=80)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Unrelated film (control group, n=55)
Number of subjects: 135
Study: 18631958

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 641

Group type: COMPARATOR
Intervention: Donepezil 10 mg daily (background therapy)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging substudy
Number of subjects: 641
Study: 15114097

Group type: EXPERIMENTAL
Intervention: Induction (T-cell-depleting and interleukin-2 receptor antibodies)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Non-induction
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Induction
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: T-cell-depleting antibody induction
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Anti-interleukin-2 receptor antibodies
Number of subjects: 174
Study: 11240440

Group type: EXPERIMENTAL
Intervention: Height (independent variable)
Number of subjects: 1284
Study: 9302546

Group type: EXPERIMENTAL
Intervention: Concern about gaining weight due to quitting smoking
Number of subjects: 242
Study: 8224951

Group type: COMPARATOR
Intervention: Argon laser treatment (ALT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Diode laser treatment (DLT)
Number of subjects: 44
Study: 3704568

Group type: EXPERIMENTAL
Intervention: terodiline
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: terodiline withdrawal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: bladder training programme
Number of subjects: 20
Study: 11180308

Group type: EXPERIMENTAL
Intervention: Minimum variance weights
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uniform weights
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cluster size weights
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study: 31063408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29510704

Group type: EXPERIMENTAL
Intervention: Traditional Yoga (TY)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 94
Study: 27663118

Group type: EXPERIMENTAL
Intervention: Immediate TMS treatment (n=7)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Delayed TMS treatment (n=3)
Number of subjects: 10
Study: 25420793

Group type: COMPARATOR
Intervention: Intradermal sodium stibogluconate (SSG)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: HF-EC followed by MWT with 0.045% DAC N-055
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: MWT with 0.045% DAC N-055 in basic crème alone
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Group II (HF-EC + DAC N-055)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Group I (SSG)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Group III (DAC N-055 alone)
Number of subjects: 87
Study: 22396225

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study: 21410042

Group type: EXPERIMENTAL
Intervention: Closed-suction drain
Number of subjects: 112

Group type: COMPARATOR
Intervention: Open (Penrose) drain
Number of subjects: 112
Study: 17432693

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (Ginaton) 0.5 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (St. Thomas' cardioplegic solution only)
Number of subjects: 30
Study: 17469410

Group type: EXPERIMENTAL
Intervention: Transendoscopic saline injection with or without epinephrine + coaptive bipolar electrocoagulation or heater probe
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antisecretory agents at high doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hp eradication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Argon plasma electrocoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanical methods such as endoclips or banding
Number of subjects: 0
Study: 12190367

Group type: EXPERIMENTAL
Intervention: homocysteine-lowering therapy with folic acid (1 mg/d), vitamin B12 (400 micro g/d), and vitamin B6 (10 mg/d) (n = 272)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6
Number of subjects: 553

Group type: COMPARATOR
Intervention: placebo (n = 281)
Number of subjects: 553

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 553
Study: 10202868

Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (200 mg three times daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: IM progesterone (50 mg daily)
Number of subjects: 100
Study: 7795309

Group type: EXPERIMENTAL
Intervention: N-acetylcystein (NAC) administration as a bolus of 100 mg/kg followed by a continuous infusion of 20 mg/kg/h during cardiopulmonary bypass (CPB)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2121769

Group type: EXPERIMENTAL
Intervention: recombinant human IFN gamma (rhIFN gamma; 10(6) U/m2.day, im, 3 times/week) for 16 weeks
Number of subjects: 11
Study: 101223

Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg, 50 mg, and 100 mg twice daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg thrice daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Atenolol once daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Atenolol twice daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Atenolol (once or twice daily)
Number of subjects: 14
Study: 31506192

Group type: EXPERIMENTAL
Intervention: MomsTalkShots educational application
Number of subjects: 1103
Study: 29534700

Group type: EXPERIMENTAL
Intervention: PEACH™ face-to-face program (1122 children, 919 families)
Number of subjects: 1513

Group type: EXPERIMENTAL
Intervention: PEACH™ Online (391 children, 297 families)
Number of subjects: 1513

Group type: COMPARATOR
Intervention: Pilot phase
Number of subjects: 1513

Group type: COMPARATOR
Intervention: State-wide program
Number of subjects: 1513
Study: 27599598

Group type: EXPERIMENTAL
Intervention: FSC 50/250 μg via Rotacaps/Rotahaler
Number of subjects: 0

Group type: COMPARATOR
Intervention: FSC 50/250 μg via Diskus
Number of subjects: 0

Group type: COMPARATOR
Intervention: FSC 50/250 μg via Rotacaps/Rotahaler and Diskus
Number of subjects: 0
Study: 24147895

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg day(-1)) and zinc sulphate (220 mg day(-1))
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg day(-1))
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Zinc sulphate (220 mg day(-1))
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 22209625

Group type: EXPERIMENTAL
Intervention: Capsaicin (TRPV1 agonist)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cinnamaldehyde (TRPA1 agonist)
Number of subjects: 56
Study: 21144968

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 3687

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 3687
Study: 17920402

Group type: EXPERIMENTAL
Intervention: Preimplantation genetic screening (PGS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 16268753

Group type: EXPERIMENTAL
Intervention: Disease management
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Augmented disease management
Number of subjects: 1069

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 1069
Study: 14525630

Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV) during nebulizer treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Assisted mucus clearance techniques without IPV
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Heart rate, respiratory rate, oxyhemoglobin saturation, end‐tidal carbon dioxide, airway resistance, and peak expiratory flow
Number of subjects: 8
Study: 10770541

Group type: EXPERIMENTAL
Intervention: GM‐CSF (sargramostim) 250 microg subcutaneous injections three times per week for 24 weeks
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: GM‐CSF
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study: 8644688

Group type: EXPERIMENTAL
Intervention: n‐3 PUFA ethyl esters
Number of subjects: 20

Group type: COMPARATOR
Intervention: olive oil (placebo)
Number of subjects: 20
Study: 1900410

Group type: EXPERIMENTAL
Intervention: Intravenous etidronate disodium (136 patients)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Saline alone (66 patients)
Number of subjects: 202
Study: 6342458

Group type: EXPERIMENTAL
Intervention: Nitrous oxide, oxygen and halothane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assisted ventilation, tracheal intubation with halothane and oxygen
Number of subjects: 0
Study: 29851826

Group type: EXPERIMENTAL
Intervention: Acupuncture at a single BL1 acupoint, 3 times per week for 8 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Artificial tears, 4 times per day for 8 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 120

Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 120
Study: 27112319

Group type: EXPERIMENTAL
Intervention: Fear of Recurrence Therapy (FORT) intervention
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (structurally equivalent support group)
Number of subjects: 144
Study: 24644301

Group type: EXPERIMENTAL
Intervention: Quadrupled semitendinosus tendon (ST) graft
Number of subjects: 135

Group type: COMPARATOR
Intervention: Bone-patellar tendon-bone (BPTB) graft
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Meniscus resection
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Overall OA prevalence
Number of subjects: 135
Study: 22777592

Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli vaginal tablets (L. brevis CD2, L. salivarius subsp. salicinius, L. plantarum)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Vaginal pH tablet (active comparator)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli vaginal tablets
Number of subjects: 159
Study: 20099949

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP) - 10-week intensive depression-focused intervention
Number of subjects: 257

Group type: COMPARATOR
Intervention: Health and Wellness (HW) control
Number of subjects: 257
Study: 17476489

Group type: EXPERIMENTAL
Intervention: Training of isolated voluntary activation of TrA
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sit-up training to activate TrA in a non-isolated manner
Number of subjects: 22
Study: 16167458

Group type: EXPERIMENTAL
Intervention: Antipsychotic polypharmacy (APP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 0
Study: 12183688

Group type: EXPERIMENTAL
Intervention: d‐amphetamine (30 mg oral dose)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 9990363

Group type: EXPERIMENTAL
Intervention: Calcipotriol (Dovonex) ointment (50 micrograms/g) twice daily for up to 3 months
Number of subjects: 306

Group type: COMPARATOR
Intervention: Dithranol (Dithrocream) 0.1‐2% for up to 3 months
Number of subjects: 306
Study: 8154531

Group type: EXPERIMENTAL
Intervention: Lodoxamide 0.1% ophthalmic solution
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118

Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 118
Study: 3419842

Group type: EXPERIMENTAL
Intervention: Combination of morphine (2 mg or 4 mg) and pentazocine (15 mg or 30 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Morphine (2, 4, 8 or 16 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pentazocine (15, 30 or 60 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 20
Study: 31639063

Group type: EXPERIMENTAL
Intervention: Low-dose haMPCs (1.0 × 10^7 cells)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mid-dose haMPCs (2.0 × 10^7 cells)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-dose haMPCs (5.0 × 10^7 cells)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All doses of haMPCs
Number of subjects: 18
Study: 30077556

Group type: EXPERIMENTAL
Intervention: Midazolam (0.25 mg kg−1) prior to alfaxalone (0.5 mg kg−1)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Alfaxalone (0.5 mg kg−1) followed by midazolam (0.25 mg kg−1)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Normal saline IV prior to alfaxalone administration (Control group)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: MA group
Number of subjects: 33
Study: 27331352

Group type: EXPERIMENTAL
Intervention: Respiratory support (mechanical ventilation or CPAP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Spontaneously breathing infants
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 60
Study: 24613534

Group type: EXPERIMENTAL
Intervention: Adjustable, single-size surgical-assist device
Number of subjects: 5
Study: 22249781

Group type: EXPERIMENTAL
Intervention: Labetalol plus standard care
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 150
Study: 19921230

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (8 IU)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 17324531

Group type: EXPERIMENTAL
Intervention: Temozolomide (Temodar) chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose escalation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemical hypoxic cell sensitizers or carbon ion therapy
Number of subjects: 0
Study: 15998892

Group type: COMPARATOR
Intervention: Placebo group of the Prostate Cancer Prevention Trial
Number of subjects: 18882

Group type: EXPERIMENTAL
Intervention: PSA cutoff values of 1.1, 2.1, 3.1, and 4.1 ng/mL
Number of subjects: 18882

Group type: EXPERIMENTAL
Intervention: PSA for detecting any prostate cancer
Number of subjects: 18882
Study: 11982474

Group type: EXPERIMENTAL
Intervention: Planned relaparotomy (PRL)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Primary abdominal closure
Number of subjects: 29
Study: 9719123

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with mitomycin C and bleomycin (group B)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Radiotherapy alone (group A)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with mitomycin C and bleomycin (group B) in oropharyngeal carcinoma
Number of subjects: 64

Group type: COMPARATOR
Intervention: Radiotherapy alone (group A) in oropharyngeal carcinoma
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combined therapy (as in arm B) in consecutive patients after December 1993
Number of subjects: 64
Study: 7864317

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 30
Study: 2606592

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone/Timolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1205270

Group type: EXPERIMENTAL
Intervention: Transpyloric tube
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ordinary solid meal
Number of subjects: 0
Study: 6991659

Group type: EXPERIMENTAL
Intervention: Electronic monitoring alone
Number of subjects: 690

Group type: COMPARATOR
Intervention: Auscultation alone
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Electronic monitoring with option to obtain fetal scalp pH
Number of subjects: 690
Study: 30977301

Group type: EXPERIMENTAL
Intervention: LCIG-HV formulation
Number of subjects: 28

Group type: COMPARATOR
Intervention: LCIG-LV formulation
Number of subjects: 28
Study: 28916371

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus docetaxel
Number of subjects: 530

Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 530
Study: 26458906

Group type: EXPERIMENTAL
Intervention: Continuous and tailored counseling delivered by village doctors for 5 years
Number of subjects: 2160

Group type: COMPARATOR
Intervention: Delayed intervention (no counseling for the first 5 years)
Number of subjects: 2160
Study: 23650072

Group type: EXPERIMENTAL
Intervention: AZD9272
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 21494175

Group type: EXPERIMENTAL
Intervention: HAV vaccine (2 doses, 6 to 9 months apart)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: HAV vaccine coadministered with DTaP and Hib vaccines (2 doses of HAV vaccine, 6 to 9 months apart)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: DTaP and Hib vaccines followed by HAV vaccine (DTaP and Hib at 15 months, HAV 30 days later, second dose of HAV 7 to 10 months after DTaP+Hib)
Number of subjects: 394
Study: 19782785

Group type: EXPERIMENTAL
Intervention: NYHA functional class II
Number of subjects: 1758

Group type: COMPARATOR
Intervention: Beta-blockers, aldosterone antagonists, CRT therapy
Number of subjects: 1758

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1758
Study: 17370488

Group type: EXPERIMENTAL
Intervention: Acupuncture at Neiguan (PC 6), Shenmen (HT 7), Danzhong (CV 17)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravenous injection of amiodarone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 80
Study: 15215025

Group type: EXPERIMENTAL
Intervention: Aircast FoamWalker boot
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fiberglass cast
Number of subjects: 12

Group type: COMPARATOR
Intervention: Barefoot walking
Number of subjects: 12
Study: 11174621

Group type: EXPERIMENTAL
Intervention: Zinc supplementation 5 mg/d (SG)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Lactose placebo (PG)
Number of subjects: 150
Study: 9753804

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (Group 1, n = 29)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Intramuscular narcotic injections (Group 2, n = 30)
Number of subjects: 59
Study: 8154809

Group type: EXPERIMENTAL
Intervention: Tactile sensation (TS) classified as malignant (gritty)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Tactile sensation (TS)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Fine needle aspiration cytology (FNAC)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Combination of TS and FNAC
Number of subjects: 169
Study: 3144941

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (15 mg/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (1 g/m2 body surface area)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intramuscular sodium aurothiomalate (up to 100 mg/week)
Number of subjects: 13
Study: 27521574

Group type: EXPERIMENTAL
Intervention: Atomoxetine (80-100 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 0
Study: 30691745

Group type: EXPERIMENTAL
Intervention: Electric current combined with simultaneous muscle stretching (EME technique)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Electrical current (EC) alone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (EME and EC)
Number of subjects: 48
Study: 27885061

Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg/day (5 days at baseline and 3 days at Month 12)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous interferon beta‐1a 44 µg three times/week
Number of subjects: 0
Study: 26422822

Group type: EXPERIMENTAL
Intervention: Transdiagnostic cognitive behavior therapy (TD‐CBT)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Disorder-specific cognitive behavior therapy (DS‐CBT)
Number of subjects: 290
Study: 23206837

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting balloons (PEB)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 402
Study: 21753868

Group type: EXPERIMENTAL
Intervention: Behavioral treatment consisting of daily pelvic floor muscle training with weekly supervision for 2 months.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Follow-up after treatment for 2 months.
Number of subjects: 14
Study: 19157574

Group type: EXPERIMENTAL
Intervention: PlasmaKnife
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bipolar dissection
Number of subjects: 100
Study: 16970532

Group type: EXPERIMENTAL
Intervention: Johrei healing (three 20-minute sessions for 5 weeks)
Number of subjects: 21
Study: 25796337

Group type: EXPERIMENTAL
Intervention: M-M-R®II manufactured using recombinant human albumin (rHA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: M-M-R®II manufactured using human serum albumin (HSA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both rHA and HSA formulations
Number of subjects: 0
Study: 10601085

Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 102
Study: 8936516

Group type: EXPERIMENTAL
Intervention: terbutaline injection
Number of subjects: 20

Group type: COMPARATOR
Intervention: sterile water injection (control)
Number of subjects: 20
Study: 1750589

Group type: EXPERIMENTAL
Intervention: Thoracic epidural fentanyl
Number of subjects: 58

Group type: COMPARATOR
Intervention: Lumbar epidural fentanyl
Number of subjects: 58
Study: 6808622

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (administered via metered dose aerosol at a lower dose than currently used)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30867157

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard wound management
Number of subjects: 0
Study: 29678969

Group type: EXPERIMENTAL
Intervention: Modification of the EHR to default to a dispense quantity of 10 tablets
Number of subjects: 36

Group type: COMPARATOR
Intervention: No EHR change (control)
Number of subjects: 36